



Platinum Anti-tumor Drugs Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2026-01-02	117	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Platinum Anti-tumor Drugs market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Platinum Anti-tumor Drugs market is projected to increase from US\$ million in 2026 to US\$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Platinum Anti-tumor Drugs market is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

Asia Pacific: the Platinum Anti-tumor Drugs market is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Platinum Anti-tumor Drugs include Teva, Sun Pharma, Sanofi, Novartis, Pfizer, Hengrui Medicine, Yi Bai Pharmaceutical, Viatrix and SK Chemicals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Platinum Anti-tumor Drugs market in terms of revenue (US\$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Platinum Anti-tumor Drugs.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Platinum Anti-tumor Drugs Market by Company

Teva

Sun Pharma

Sanofi

Novartis

Pfizer
Hengrui Medicine
Yi Bai Pharmaceutical
Viatris
SK Chemicals
Qilu Pharmaceutical
Dr Reddy's Laboratories
Debiopharm
ASK Pharma
Accord Healthcare

Platinum Anti-tumor Drugs Segment by Type

Oxaliplatin
Carboplatin
Cisplatin
Other

Platinum Anti-tumor Drugs Segment by Application

Ovarian Cancer
Lung Cancer
Colorectal Cancer
Other

Platinum Anti-tumor Drugs Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Platinum Anti-tumor Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Platinum Anti-tumor Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Platinum Anti-tumor Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4:

Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5:

Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6:

Detailed analysis of Platinum Anti-tumor Drugs companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Platinum Anti-tumor Drugs by Type
 - 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
 - 2.2.2 Oxaliplatin
 - 2.2.3 Carboplatin
 - 2.2.4 Cisplatin
 - 2.2.5 Other
- 2.3 Platinum Anti-tumor Drugs by Application
 - 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.3.2 Ovarian Cancer
 - 2.3.3 Lung Cancer
 - 2.3.4 Colorectal Cancer
 - 2.3.5 Other
- 2.4 Assumptions and Limitations

3 Platinum Anti-tumor Drugs Breakdown Data by Type

- 3.1 Global Platinum Anti-tumor Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Platinum Anti-tumor Drugs Forecasted Market Size by Type (2027-2032)

4 Platinum Anti-tumor Drugs Breakdown Data by Application

- 4.1 Global Platinum Anti-tumor Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Platinum Anti-tumor Drugs Forecasted Market Size by Application (2027-2032)

5 Global Growth Trends

- 5.1 Global Platinum Anti-tumor Drugs Market Perspective (2021-2032)
- 5.2 Global Platinum Anti-tumor Drugs Growth Trends by Region
 - 5.2.1 Global Platinum Anti-tumor Drugs Market Size by Region: 2021 VS 2025 VS 2032
 - 5.2.2 Platinum Anti-tumor Drugs Historic Market Size by Region (2021-2026)
 - 5.2.3 Platinum Anti-tumor Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Platinum Anti-tumor Drugs Market Dynamics
 - 5.3.1 Platinum Anti-tumor Drugs Industry Trends
 - 5.3.2 Platinum Anti-tumor Drugs Market Drivers
 - 5.3.3 Platinum Anti-tumor Drugs Market Challenges
 - 5.3.4 Platinum Anti-tumor Drugs Market Restraints

6 Market Competitive Landscape by Players

- 6.1 Global Top Platinum Anti-tumor Drugs Players by Revenue

6.1.1 Global Top Platinum Anti-tumor Drugs Players by Revenue (2021-2026)

6.1.2 Global Platinum Anti-tumor Drugs Revenue Market Share by Players (2021-2026)

6.2 Global Platinum Anti-tumor Drugs Industry Players Ranking, 2023 VS 2024 VS 2025

6.3 Global Key Players of Platinum Anti-tumor Drugs Head Office and Area Served

6.4 Global Platinum Anti-tumor Drugs Players, Product Type & Application

6.5 Global Platinum Anti-tumor Drugs Manufacturers Established Date

6.6 Global Platinum Anti-tumor Drugs Market CR5 and HHI

6.7 Global Players Mergers & Acquisition

7 North America

7.1 North America Platinum Anti-tumor Drugs Market Size (2021-2032)

7.2 North America Platinum Anti-tumor Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032

7.3 North America Platinum Anti-tumor Drugs Market Size by Country (2021-2026)

7.4 North America Platinum Anti-tumor Drugs Market Size by Country (2027-2032)

7.5 United States

7.5 United States

7.6 Canada

7.7 Mexico

8 Europe

8.1 Europe Platinum Anti-tumor Drugs Market Size (2021-2032)

8.2 Europe Platinum Anti-tumor Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032

8.3 Europe Platinum Anti-tumor Drugs Market Size by Country (2021-2026)

8.4 Europe Platinum Anti-tumor Drugs Market Size by Country (2027-2032)

8.5 Germany

8.6 France

8.7 U.K.

8.8 Italy

8.9 Spain

8.10 Russia

8.11 Netherlands

8.12 Nordic Countries

9 Asia-Pacific

9.1 Asia-Pacific Platinum Anti-tumor Drugs Market Size (2021-2032)

9.2 Asia-Pacific Platinum Anti-tumor Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032

9.3 Asia-Pacific Platinum Anti-tumor Drugs Market Size by Country (2021-2026)

9.4 Asia-Pacific Platinum Anti-tumor Drugs Market Size by Country (2027-2032)

9.5 China

9.6 Japan

9.7 South Korea

9.8 India

9.9 Australia

9.10 China Taiwan

9.11 Southeast Asia

10 South America

10.1 South America Platinum Anti-tumor Drugs Market Size (2021-2032)

10.2 South America Platinum Anti-tumor Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032

10.3 South America Platinum Anti-tumor Drugs Market Size by Country (2021-2026)

10.4 South America Platinum Anti-tumor Drugs Market Size by Country (2027-2032)

- 10.5 Brazil
 - 10.6 Argentina
 - 10.7 Chile
 - 10.8 Colombia
 - 10.9 Peru
-

11 Middle East & Africa

- 11.1 Middle East & Africa Platinum Anti-tumor Drugs Market Size (2021-2032)
 - 11.2 Middle East & Africa Platinum Anti-tumor Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
 - 11.3 Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2021-2026)
 - 11.4 Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2027-2032)
 - 11.5 Saudi Arabia
 - 11.6 Israel
 - 11.7 United Arab Emirates
 - 11.8 Turkey
 - 11.9 Iran
 - 11.10 Egypt
-

12 Players Profiled

- 12.1 Teva
 - 12.1.1 Teva Company Information
 - 12.1.2 Teva Business Overview
 - 12.1.3 Teva Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
 - 12.1.4 Teva Platinum Anti-tumor Drugs Product Portfolio
 - 12.1.5 Teva Recent Developments
- 12.2 Sun Pharma
 - 12.2.1 Sun Pharma Company Information
 - 12.2.2 Sun Pharma Business Overview
 - 12.2.3 Sun Pharma Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
 - 12.2.4 Sun Pharma Platinum Anti-tumor Drugs Product Portfolio
 - 12.2.5 Sun Pharma Recent Developments
- 12.3 Sanofi
 - 12.3.1 Sanofi Company Information
 - 12.3.2 Sanofi Business Overview
 - 12.3.3 Sanofi Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
 - 12.3.4 Sanofi Platinum Anti-tumor Drugs Product Portfolio
 - 12.3.5 Sanofi Recent Developments
- 12.4 Novartis
 - 12.4.1 Novartis Company Information
 - 12.4.2 Novartis Business Overview
 - 12.4.3 Novartis Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
 - 12.4.4 Novartis Platinum Anti-tumor Drugs Product Portfolio
 - 12.4.5 Novartis Recent Developments
- 12.5 Pfizer
 - 12.5.1 Pfizer Company Information
 - 12.5.2 Pfizer Business Overview
 - 12.5.3 Pfizer Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
 - 12.5.4 Pfizer Platinum Anti-tumor Drugs Product Portfolio
 - 12.5.5 Pfizer Recent Developments
- 12.6 Hengrui Medicine

- 12.6.1 Hengrui Medicine Company Information
- 12.6.2 Hengrui Medicine Business Overview
- 12.6.3 Hengrui Medicine Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
- 12.6.4 Hengrui Medicine Platinum Anti-tumor Drugs Product Portfolio
- 12.6.5 Hengrui Medicine Recent Developments
- 12.7 Yi Bai Pharmaceutical
 - 12.7.1 Yi Bai Pharmaceutical Company Information
 - 12.7.2 Yi Bai Pharmaceutical Business Overview
 - 12.7.3 Yi Bai Pharmaceutical Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
 - 12.7.4 Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio
 - 12.7.5 Yi Bai Pharmaceutical Recent Developments
- 12.8 Viatris
 - 12.8.1 Viatris Company Information
 - 12.8.2 Viatris Business Overview
 - 12.8.3 Viatris Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
 - 12.8.4 Viatris Platinum Anti-tumor Drugs Product Portfolio
 - 12.8.5 Viatris Recent Developments
- 12.9 SK Chemicals
 - 12.9.1 SK Chemicals Company Information
 - 12.9.2 SK Chemicals Business Overview
 - 12.9.3 SK Chemicals Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
 - 12.9.4 SK Chemicals Platinum Anti-tumor Drugs Product Portfolio
 - 12.9.5 SK Chemicals Recent Developments
- 12.10 Qilu Pharmaceutical
 - 12.10.1 Qilu Pharmaceutical Company Information
 - 12.10.2 Qilu Pharmaceutical Business Overview
 - 12.10.3 Qilu Pharmaceutical Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
 - 12.10.4 Qilu Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio
 - 12.10.5 Qilu Pharmaceutical Recent Developments
- 12.11 Dr Reddy's Laboratories
 - 12.11.1 Dr Reddy's Laboratories Company Information
 - 12.11.2 Dr Reddy's Laboratories Business Overview
 - 12.11.3 Dr Reddy's Laboratories Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
 - 12.11.4 Dr Reddy's Laboratories Platinum Anti-tumor Drugs Product Portfolio
 - 12.11.5 Dr Reddy's Laboratories Recent Developments
- 12.12 Debiopharm
 - 12.12.1 Debiopharm Company Information
 - 12.12.2 Debiopharm Business Overview
 - 12.12.3 Debiopharm Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
 - 12.12.4 Debiopharm Platinum Anti-tumor Drugs Product Portfolio
 - 12.12.5 Debiopharm Recent Developments
- 12.13 ASK Pharma
 - 12.13.1 ASK Pharma Company Information
 - 12.13.2 ASK Pharma Business Overview
 - 12.13.3 ASK Pharma Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
 - 12.13.4 ASK Pharma Platinum Anti-tumor Drugs Product Portfolio
 - 12.13.5 ASK Pharma Recent Developments
- 12.14 Accord Healthcare

12.14.1 Accord Healthcare Company Information

12.14.2 Accord Healthcare Business Overview

12.14.3 Accord Healthcare Revenue in Platinum Anti-tumor Drugs Business (2021-2026)

12.14.4 Accord Healthcare Platinum Anti-tumor Drugs Product Portfolio

12.14.5 Accord Healthcare Recent Developments

13 Report Conclusion

14 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Platinum Anti-tumor Drugs Market Size by Type (2021-2026) & (US\$ Million)
- Table 6: Global Platinum Anti-tumor Drugs Revenue Market Share by Type (2021-2026)
- Table 7: Global Platinum Anti-tumor Drugs Forecasted Market Size by Type (2027-2032) & (US\$ Million)
- Table 8: Global Platinum Anti-tumor Drugs Revenue Market Share by Type (2027-2032)
- Table 9: Global Platinum Anti-tumor Drugs Market Size by Application (2021-2026) & (US\$ Million)
- Table 10: Global Platinum Anti-tumor Drugs Revenue Market Share by Application (2021-2026)
- Table 11: Global Platinum Anti-tumor Drugs Forecasted Market Size by Application (2027-2032) & (US\$ Million)
- Table 12: Global Platinum Anti-tumor Drugs Revenue Market Share by Application (2027-2032)
- Table 13: Global Platinum Anti-tumor Drugs Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 14: Global Platinum Anti-tumor Drugs Market Size by Region (2021-2026) & (US\$ Million)
- Table 15: Global Platinum Anti-tumor Drugs Market Share by Region (2021-2026)
- Table 16: Global Platinum Anti-tumor Drugs Forecasted Market Size by Region (2027-2032) & (US\$ Million)
- Table 17: Global Platinum Anti-tumor Drugs Market Share by Region (2027-2032)
- Table 18: Platinum Anti-tumor Drugs Industry Trends
- Table 19: Platinum Anti-tumor Drugs Industry Drivers
- Table 20: Platinum Anti-tumor Drugs Industry Opportunities and Challenges
- Table 21: Platinum Anti-tumor Drugs Market Restraints
- Table 22: Global Top Platinum Anti-tumor Drugs Players by Revenue (US\$ Million) & (2021-2026)
- Table 23: Global Platinum Anti-tumor Drugs Revenue Market Share by Players (2021-2026)
- Table 24: Global Platinum Anti-tumor Drugs Industry Players Ranking, 2024 VS 2025 VS 2026
- Table 25: Global Key Players of Platinum Anti-tumor Drugs, Headquarters and Area Served
- Table 26: Global Platinum Anti-tumor Drugs Players, Product Type & Application
- Table 27: Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28: Global Platinum Anti-tumor Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 29: Players Mergers & Acquisitions, Expansion Plans
- Table 30: North America Platinum Anti-tumor Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 31: North America Platinum Anti-tumor Drugs Market Size by Country (2021-2026) & (US\$ Million)
- Table 32: North America Platinum Anti-tumor Drugs Market Size by Country (2027-2032) & (US\$ Million)
- Table 33: Europe Platinum Anti-tumor Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 34: Europe Platinum Anti-tumor Drugs Market Size by Country (2021-2026) & (US\$ Million)
- Table 35: Europe Platinum Anti-tumor Drugs Market Size by Country (2027-2032) & (US\$ Million)
- Table 36: Asia Pacific Platinum Anti-tumor Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 37: Asia Pacific Platinum Anti-tumor Drugs Market Size by Region (2021-2026) & (US\$ Million)
- Table 38: Asia Pacific Platinum Anti-tumor Drugs Market Size by Country (2027-2032) & (US\$ Million)
- Table 39: South America Platinum Anti-tumor Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 40: South America Platinum Anti-tumor Drugs Market Size by Country (2021-2026) & (US\$ Million)
- Table 41: South America Platinum Anti-tumor Drugs Market Size by Country (2027-2032) & (US\$ Million)
- Table 42: Middle East & Africa Platinum Anti-tumor Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 43: Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2021-2026) & (US\$ Million)
- Table 44: Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2027-2032) & (US\$ Million)
- Table 45: Teva Company Information
- Table 46: Teva Business Overview
- Table 47: Teva Revenue in Platinum Anti-tumor Drugs Business (2021-2026) & (US\$ Million)
- Table 48: Teva Platinum Anti-tumor Drugs Product Portfolio
- Table 49: Teva Recent Developments
- Table 50: Sun Pharma Company Information
- Table 51: Sun Pharma Business Overview
- Table 52: Sun Pharma Revenue in Platinum Anti-tumor Drugs Business (2021-2026) & (US\$ Million)
- Table 53: Sun Pharma Platinum Anti-tumor Drugs Product Portfolio
- Table 54: Sun Pharma Recent Developments

- Table 55: Sanofi Company Information
- Table 56: Sanofi Business Overview
- Table 57: Sanofi Revenue in Platinum Anti-tumor Drugs Business (2021-2026) & (US\$ Million)
- Table 58: Sanofi Platinum Anti-tumor Drugs Product Portfolio
- Table 59: Sanofi Recent Developments
- Table 60: Novartis Company Information
- Table 61: Novartis Business Overview
- Table 62: Novartis Revenue in Platinum Anti-tumor Drugs Business (2021-2026) & (US\$ Million)
- Table 63: Novartis Platinum Anti-tumor Drugs Product Portfolio
- Table 64: Novartis Recent Developments
- Table 65: Pfizer Company Information
- Table 66: Pfizer Business Overview
- Table 67: Pfizer Revenue in Platinum Anti-tumor Drugs Business (2021-2026) & (US\$ Million)
- Table 68: Pfizer Platinum Anti-tumor Drugs Product Portfolio
- Table 69: Pfizer Recent Developments
- Table 70: Hengrui Medicine Company Information
- Table 71: Hengrui Medicine Business Overview
- Table 72: Hengrui Medicine Revenue in Platinum Anti-tumor Drugs Business (2021-2026) & (US\$ Million)
- Table 73: Hengrui Medicine Platinum Anti-tumor Drugs Product Portfolio
- Table 74: Hengrui Medicine Recent Developments
- Table 75: Yi Bai Pharmaceutical Company Information
- Table 76: Yi Bai Pharmaceutical Business Overview
- Table 77: Yi Bai Pharmaceutical Revenue in Platinum Anti-tumor Drugs Business (2021-2026) & (US\$ Million)
- Table 78: Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio
- Table 79: Yi Bai Pharmaceutical Recent Developments
- Table 80: Viatrix Company Information
- Table 81: Viatrix Business Overview
- Table 82: Viatrix Revenue in Platinum Anti-tumor Drugs Business (2021-2026) & (US\$ Million)
- Table 83: Viatrix Platinum Anti-tumor Drugs Product Portfolio
- Table 84: Viatrix Recent Developments
- Table 85: SK Chemicals Company Information
- Table 86: SK Chemicals Business Overview
- Table 87: SK Chemicals Revenue in Platinum Anti-tumor Drugs Business (2021-2026) & (US\$ Million)
- Table 88: SK Chemicals Platinum Anti-tumor Drugs Product Portfolio
- Table 89: SK Chemicals Recent Developments
- Table 90: Qilu Pharmaceutical Company Information
- Table 91: Qilu Pharmaceutical Business Overview
- Table 92: Qilu Pharmaceutical Revenue in Platinum Anti-tumor Drugs Business (2021-2026) & (US\$ Million)
- Table 93: Qilu Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio
- Table 94: Qilu Pharmaceutical Recent Developments
- Table 95: Dr Reddy's Laboratories Company Information
- Table 96: Dr Reddy's Laboratories Business Overview
- Table 97: Dr Reddy's Laboratories Revenue in Platinum Anti-tumor Drugs Business (2021-2026) & (US\$ Million)
- Table 98: Dr Reddy's Laboratories Platinum Anti-tumor Drugs Product Portfolio
- Table 99: Dr Reddy's Laboratories Recent Developments
- Table 100: Debiopharm Company Information
- Table 101: Debiopharm Business Overview
- Table 102: Debiopharm Revenue in Platinum Anti-tumor Drugs Business (2021-2026) & (US\$ Million)
- Table 103: Debiopharm Platinum Anti-tumor Drugs Product Portfolio
- Table 104: Debiopharm Recent Developments
- Table 105: ASK Pharma Company Information
- Table 106: ASK Pharma Business Overview
- Table 107: ASK Pharma Revenue in Platinum Anti-tumor Drugs Business (2021-2026) & (US\$ Million)
- Table 108: ASK Pharma Platinum Anti-tumor Drugs Product Portfolio
- Table 109: ASK Pharma Recent Developments
- Table 110: Accord Healthcare Company Information
- Table 111: Accord Healthcare Business Overview
- Table 112: Accord Healthcare Revenue in Platinum Anti-tumor Drugs Business (2021-2026) & (US\$ Million)
- Table 113: Accord Healthcare Platinum Anti-tumor Drugs Product Portfolio
- Table 114: Accord Healthcare Recent Developments
- Table 115: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Platinum Anti-tumor Drugs Product Image
- Figure 5: Global Platinum Anti-tumor Drugs Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 6: Global Platinum Anti-tumor Drugs Market Share by Type: 2025 VS 2032
- Figure 7: Oxaliplatin Product
- Figure 8: Carboplatin Product
- Figure 9: Cisplatin Product
- Figure 10: Other Product
- Figure 11: Global Platinum Anti-tumor Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 12: Global Platinum Anti-tumor Drugs Market Share by Application: 2025 VS 2032
- Figure 13: Ovarian Cancer Product
- Figure 14: Lung Cancer Product
- Figure 15: Colorectal Cancer Product
- Figure 16: Other Product
- Figure 17: Global Platinum Anti-tumor Drugs Market Size (US\$ Million), Year-over-Year: 2021-2032
- Figure 18: Global Platinum Anti-tumor Drugs Market Size, (US\$ Million), 2021 VS 2025 VS 2032
- Figure 19: Global Platinum Anti-tumor Drugs Market Share by Region: 2025 VS 2032
- Figure 20: Global Platinum Anti-tumor Drugs Market Share by Players in 2025
- Figure 21: Global Platinum Anti-tumor Drugs Manufacturers Established Date
- Figure 22: Global Top 5 and 10 Platinum Anti-tumor Drugs Players Market Share by Revenue in 2025
- Figure 23: Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 24: North America Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 25: North America Platinum Anti-tumor Drugs Market Share by Country (2021-2032)
- Figure 26: United States Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 27: Canada Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 28: Mexico Platinum Anti-tumor Drugs Market Share by Country (2021-2032)
- Figure 29: Europe Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 30: Europe Platinum Anti-tumor Drugs Market Share by Country (2021-2032)
- Figure 31: Germany Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 32: France Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 33: U.K. Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 34: Italy Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 35: Spain Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 36: Russia Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 37: Netherlands Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 38: Nordic Countries Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 39: Asia-Pacific Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 40: Asia-Pacific Platinum Anti-tumor Drugs Market Share by Country (2021-2032)
- Figure 41: China Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 42: Japan Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 43: South Korea Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 44: India Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 45: India Platinum Anti-tumor Drugs Market Share by Country (2021-2032)
- Figure 46: Australia Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 47: China Taiwan Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 48: Southeast Asia Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 49: South America Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 50: South America Platinum Anti-tumor Drugs Market Share by Country (2021-2032)
- Figure 51: Brazil Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 52: Argentina Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 53: Chile Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 54: Colombia Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 55: Peru Platinum Anti-tumor Drugs Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 56: Teva Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2021-2026)
- Figure 57: Sun Pharma Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2021-2026)
- Figure 58: Sanofi Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2021-2026)
- Figure 59: Novartis Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2021-2026)
- Figure 60: Pfizer Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2021-2026)
- Figure 61: Hengrui Medicine Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2021-2026)
- Figure 62: Yi Bai Pharmaceutical Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2021-2026)
- Figure 63: Viatris Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2021-2026)
- Figure 64: SK Chemicals Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2021-2026)

- Figure 65: Qilu Pharmaceutical Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2021-2026)
- Figure 66: Dr Reddy's Laboratories Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2021-2026)
- Figure 67: Debiopharm Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2021-2026)
- Figure 68: ASK Pharma Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2021-2026)
- Figure 69: Accord Healthcare Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2021-2026)